SBIR/STTR Research Award

Development of Rx100 as Novel Medical Countermeasure for Acute Radiation Syndrome

Award identifier 5dfacece0191b2b9c5842a578bd6635b5e6e4e2601dedfb22475c8c8b81a4270Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$297,087

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Rxbio, Inc.
Proposal award date
2015-03-01
Contract end date
2016-05-31
UEI
DB9LSMAHKNJ8
Solicitation number
PA12-044
Topic code
NIAID

Research abstract

DESCRIPTION provided by applicant The looming threat of nuclear attacks and recent non terrorist related accidents Fukushima nuclear disaster has increased national and global attention to the need for medical countermeasures RxBio has identified a first in class proprietary small molecule Rx which significantly protects the gut and the hematopoietic system from exposure to lethal doses of ionizing radiation We have demonstrated the radiomitigant efficacy of Rx in murine and non human primate NHP models for GI ARS Gastrointestinal Acute Radiation Syndrome RxBio has completed a spectrum of drug development activities in consultation with FDA The overall goal of this proposal is to complete manufacturing chemistry studies to support regulatory activities in advancing Rx lysine for eventual FDA licensure The Phase I program specific aims are to evaluate the raw material standards for acceptance to manufacture highly pure Rx lysine by examining the stability of oleyl alcohol and investigating potential degraded or source impurities of oleyl alcohol via identification and structural characterization and to investigate process improvement studies and stressing of current chemistry process in each manufacturing step and demonstrate the robustness of modified process via lab scale synthesis of highly pure API Proposed studies will be completed in months with two major deliverables a Establishing the acceptance criteria for oleyl alcohol for GMP scale up effort th month b Improved manufacturing process to generate highly pure Rx lysine and batch record for lab scale synthesis effort th month PUBLIC HEALTH RELEVANCE Inevitably nuclear accidents occur and nuclear attacks and radiation terrorism have become a real threat to our nation since September Currently there are no FDA approved medical countermeasures available today for treating radiation injury We are proposing to develop a novel class of radiation medical countermeasures to protect the American people and mankind from radiation injury

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2007–2020). Reported award amounts total $1,163,980. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.